Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.52 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | CALCR | P30988 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727004 | 0.86 | AGTR2 (0.47) | CALCRLEP300HIF1AXIAPENPEP | |
| SCHEMBL29727005 | 0.86 | AGTR2 (0.47) | CALCRLEP300HIF1AXIAPENPEP | |
| SCHEMBL30275918 | 0.84 | CALCRL (0.47) | CALCRLRAMP1EP300HIF1ANTSR1 | |
| SCHEMBL30785091 | 0.84 | RAMP3 (0.50) | CALCRLEP300HIF1ACALCR | |
| SCHEMBL30150576 | 0.83 | CALCRL (0.47) | CALCRLRAMP1XIAPAGTR1AGTR2 | |
| SCHEMBL30067104 | 0.83 | PTPN1 (0.48) | CALCRLPTPN1EP300HIF1ANTSR2 | |
| SCHEMBL31461906 | 0.82 | F2 (0.47) | EP300HIF1ANTSR2NTSR1CALCR | |
| SCHEMBL30432780 | 0.82 | F2 (0.53) | EP300HIF1ACALCR | |
| SCHEMBL30816314 | 0.82 | PTPN1 (0.46) | CALCRLRAMP1PTPN1XIAPENPEP | |
| SCHEMBL31182928 | 0.81 | CAPN1 (0.51) | CALCRLEP300HIF1ANTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391956-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-11-14 | — | — | US | disclosed |
| US-11981706-B2 | Parvovirus structural protein for the treatment of autoimmune diseases | 2A PHARMA AB (SE) | 2024-05-14 | — | — | US | disclosed |
| US-20240043824-A1 | MULTIMERIC PROTEINS OF THE PEROXIREDOXIN FAMILY AS SCAFFOLD PROTEINS | CATSALYZE (FR) | 2024-02-08 | — | — | US | disclosed |
| US-20230312655-A1 | PARVOVIRUS STRUCTURAL PROTEIN FOR THE TREATMENT OF AUTOIMMUNE DISEASES | 2A PHARMA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-11718683-B2 | Antigen-binding fusion proteins with modified HSP70 domains | APERISYS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11492377-B2 | Parvovirus structural protein for the treatment of autoimmune diseases | 2A PHARMA AB (SE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391956-A1 | STAPLED PEPTIDES AND METHODS THEREOF | MDM2, STUB1, TP53 | CALCRL 1564/4885RAMP1 3774/4885PTPN1 1427/4885 |
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | VIP, IAPP, GLP1R | CALCRL 51/4885RAMP1 3469/4885PTPN1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.